Search

Your search keyword '"Einsele, H."' showing total 2,299 results

Search Constraints

Start Over You searched for: Author "Einsele, H." Remove constraint Author: "Einsele, H."
2,299 results on '"Einsele, H."'

Search Results

2. Real-world analysis of teclistamab in 123 RRMM patients from Germany

4. POS0241 GENOME-WIDE METHYLATION PROFILES OF PERIPHERAL WHOLE BLOOD IN NEWLY DIAGNOSED GIANT CELL ARTERITIS OR POLYMYALGIA RHEUMATICA

5. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

8. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

9. Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

11. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

14. P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY

15. P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

16. P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID

18. P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA

19. P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS

20. P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN

21. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

22. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)

24. Second primary malignancies in multiple myeloma: an overview and IMWG consensus

25. Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium

32. CXCR4-gerichtete PET/CT in 100 Patient:innen mit Marginalzonenlymphom -Diagnostische Performance, Vorhersagepotenzial und Eignung für CXCR4-Endoradiotherapie

34. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT

37. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

43. Recording of the regional origin areas of patients from the molecular tumor board to identify the 'white spots' in the service area - a joint initiative of the Bavarian CCC WERA alliance [Abstract]

45. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

46. Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”

50. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Catalog

Books, media, physical & digital resources